Free Trial
NYSE:CTLT

Catalent (CTLT) Stock Price, News & Analysis

Catalent logo
$61.00 +0.25 (+0.41%)
(As of 11/27/2024 ET)

About Catalent Stock (NYSE:CTLT)

Key Stats

Today's Range
$60.70
$61.05
50-Day Range
$58.48
$61.24
52-Week Range
$36.74
$61.50
Volume
1.50 million shs
Average Volume
2.04 million shs
Market Capitalization
$11.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.40
Consensus Rating
Hold

Company Overview

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Catalent Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
66th Percentile Overall Score

CTLT MarketRank™: 

Catalent scored higher than 66% of companies evaluated by MarketBeat, and ranked 408th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Catalent has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Catalent has only been the subject of 3 research reports in the past 90 days.

  • Read more about Catalent's stock forecast and price target.
  • Earnings Growth

    Earnings for Catalent are expected to grow by 63.10% in the coming year, from $0.84 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Catalent is -26.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Catalent is -26.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Catalent has a PEG Ratio of 2.44. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Catalent has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Catalent's valuation and earnings.
  • Percentage of Shares Shorted

    4.99% of the outstanding shares of Catalent have been sold short.
  • Short Interest Ratio / Days to Cover

    Catalent has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Catalent has recently increased by 7.35%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Catalent does not currently pay a dividend.

  • Dividend Growth

    Catalent does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.99% of the outstanding shares of Catalent have been sold short.
  • Short Interest Ratio / Days to Cover

    Catalent has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Catalent has recently increased by 7.35%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Catalent has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Catalent this week, compared to 7 articles on an average week.
  • Search Interest

    Only 4 people have searched for CTLT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Catalent to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Catalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $305,931.00 in company stock.

  • Percentage Held by Insiders

    Only 0.31% of the stock of Catalent is held by insiders.

  • Read more about Catalent's insider trading history.
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Catalent (NYSE:CTLT) Downgraded by StockNews.com to Sell
The latest trend in real estate
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Novo slated to win EU approval for Catalent takeover, Reuters says
Catalent Stock: Analyst Estimates & Ratings
Catalent (NYSE:CTLT) Rating Increased to Hold at StockNews.com
See More Headlines

CTLT Stock Analysis - Frequently Asked Questions

Catalent's stock was trading at $44.93 on January 1st, 2024. Since then, CTLT stock has increased by 35.8% and is now trading at $61.00.
View the best growth stocks for 2024 here
.

Catalent, Inc. (NYSE:CTLT) announced its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.18. The business's revenue was up 4.2% compared to the same quarter last year.

Catalent's top institutional shareholders include State Street Corp (4.11%), Barclays PLC (2.36%), Geode Capital Management LLC (2.35%) and Alpine Associates Management Inc. (1.17%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Steven L Fasman, Scott Gunther, David Mcerlane, John J Greisch, Matti Masanovich, Ricky Hopson, Joseph Anthony Ferraro, Thomas P Castellano, Ricardo Pravda, Michael J Grippo, Kay A Schmidt, Manja Boerman, Michelle R Ryan, Michael A Riley, Mario Gargiulo, Charles Lickfold, Thomas W Hawkeswood, Ricci S Whitlow, Peter Zippelius and Karen Flynn.
View institutional ownership trends
.

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalent investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
11/05/2024
Today
11/28/2024
Next Earnings (Estimated)
2/14/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
16,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.40
High Stock Price Target
$63.50
Low Stock Price Target
$63.00
Potential Upside/Downside
+3.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-1,043,000,000.00
Pretax Margin
-7.83%

Debt

Sales & Book Value

Annual Sales
$4.38 billion
Cash Flow
$2.61 per share
Book Value
$19.51 per share

Miscellaneous

Free Float
180,949,000
Market Cap
$11.07 billion
Optionable
Optionable
Beta
1.16

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NYSE:CTLT) was last updated on 11/28/2024 by MarketBeat.com Staff
From Our Partners